Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Licensing deals
Biotech
Will COINS Act kill China biotech licensing boom?
Amid China’s rapid biotech ascent, a growing chorus in the U.S. wants biotechnology added to the COINS Act to restrict outbound capital flows.
Angus Liu
May 26, 2026 3:50pm
Astellas targets more deals, cost cutting to swerve patent cliff
May 26, 2026 7:35am
How rising cost to license drugs from China is changing the game
May 19, 2026 9:00am
Regeneron pens $2.3B Parabilis pact to develop new twist on ADCs
May 18, 2026 9:08am
Fosun pays $60M for option on AriBio’s phase 3 Alzheimer’s asset
May 13, 2026 9:15am
Boehringer makes €407M bet on Immunitas’ inflammatory asset
May 12, 2026 9:57am
